Ozempic tied to cardiometabolic benefits, may lower CVD risk in type 1 diabetes

Janet Snell-Bergeon, professor of pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus, said investigating therapies that can reduce CVD risk in type 1 diabetes is important due to the increased risk for adverse CV outcomes the population faces at a younger age.